TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: The knowledge of the importance of this gene in CML progression goes back to 1998 when two independent studies reported a common deletion at 17p13.3 in leukemia [89] and molecular alterations in the TP53 gene in cells from CML patients [90].